Drug intelligence / Profile preview

lysine chloride

Development stage: Phase 1
Lead developer: Yale University
Modality: Small Molecules
Administration: Oral

Overview

Lysine chloride is an investigational sodium-free chloride supplement being developed by Yale University for the treatment of heart failure, particularly in patients with hypochloremia and diuretic resistance. It consists of the essential amino acid L-lysine paired with a chloride ion, allowing for the delivery of supplemental chloride without the co-administration of sodium. By replenishing chloride levels, the compound is hypothesized to modulate renal salt sensing and neurohormonal activation (such as the renin-angiotensin-aldosterone system), thereby improving diuretic responsiveness and volume status. It is currently being evaluated in clinical trials (e.g., NCT03440970) as an oral therapy.

Other names: L-lysine hydrochlorideL-lysine chloridesodium-free chloride supplement

Beyond the preview

Go deeper on lysine chloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lysine chloride.

Explore the full profile